Rome, Italy
Research view
Endometrial cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- TP53 8
- PD-1 17
- HER2 13
- PTEN 3
- PI3K 7
- PD-L1 6
- mTOR 2
- AKT 2
- CTNNB1 1
- PIK3CA 6
- ARID1A 3
- BRCA1 2
- KRAS 5
- PARP 3
- VEGF 2
- CDK4/6 3
- ERK 0
- GLP-1 3
- STAT3 0
- TROP2 3
- BRCA2 1
- CTLA-4 2
- MAPK 0
- ESR1 0
- AR 0
- ATM 1
- AMPK 1
- AXL 2
- B7-H3 2
- COX-2 0
- FGFR 0
- IGF1R 0
- TIGIT 1
- BCL-2 0
- FTO 0
- GPX4 0
- HDAC 0
- HER3 1
- PALB2 1
- RAS 1
- BRAF 0
- EGFR 2
- EZH2 0
- JAK 0
- JNK 0
- KEAP1 1
- LAG-3 0
- MDM2 0
- MET 0
- MMP-9 0
- NLRP3 0
- PRAME 1
- PSMA 1
- SGLT2 1
- STING 0
- STK11 1
- APOE 0
- CD20 0
- CD47 0
- CDKN2A 0
EU-13 is a filter, not a ranking: it only narrows the list.
Chapel Hill, United States
Montreal, Canada
New York, United States
Beijing, China
Barcelona, Spain
New Haven, United States
Birmingham, United States
Milan, Italy
Leiden, Netherlands
Ann Arbor, United States
Stockholm, Sweden
Berlin, Germany
Milan, Italy
Brigham and Women's Hospital · Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Mil Med Res, Nov 2025Diverging global incidence trends of early-onset cancers: comparisons with incidence trends of later-onset cancers and mortality trends of early-onset cancers.
Toronto, Canada
Guangzhou, China
Durham, United States
Shanghai, China
Beijing, China
Innsbruck, Austria
Copenhagen, Denmark
Fuzhou, China
Leuven, Belgium
24 of 62+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
“Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source
Terminated
“Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.”Registry text, quoted unchanged. Source
Withdrawn
“Slow Accrual”Registry text, quoted unchanged. Source
Suspended
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
“Company decision”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 8
- Organoids 3
- Mendelian Randomization Analysis 13
- CRISPR-Cas Systems 5
- Gene Expression Profiling 37
- Sequence Analysis, RNA 1
- Exome Sequencing 6
- Proteomics 17
- Metabolomics 7
- Mass Spectrometry 1
- Flow Cytometry 1
- Immunohistochemistry 85
- Liquid Biopsy 4
- Circulating Tumor DNA 9
- Xenograft Model Antitumor Assays 38
- Positron-Emission Tomography 4
- Magnetic Resonance Imaging 36
- Machine Learning 35
- Deep Learning 18
- Cohort Studies 82
- Genome-Wide Association Study 11
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.